Clinical Trial Update: Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial results for Epoprostenol for Injection in patients with pulmonary arterial hypertension have been posted. The study was sponsored by Actelion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Epoprostenol for Injection (epoprostenol)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2016-12-09